ASSESSMENT OF THE EFFECT OF UNOS NEW CPRA CALCULATOR IMPLEMENTED IN JANUARY 2023 , ON RATE OF TRANSPLANT FOR SENSITIZED AND NON-SENSITIZED DECEASED KIDNEY AND PANCREAS TRANSPLANT, FOR PATIENT POPULATION FOR PATIENT POPULATION AT CEDARS SINAI MEDICAL CENTER

AUTHOR BLOCK: Mehrnoush R. Naim, Geraldine Ong, Qi Wang, Nicola Layne, Sharon Daroy, Ernie Bustamante JR, Desiree Magat, Brittany Helmer, Xiaohai Zhang, Cedars sinai Medical Cener, Los Angeles CA.

Abstract:

Background: In January 2023, UNOS implemented a new CPRA calculator based on HLA typing of NMDP donors. In addition, the new calculator included HLA-DQA1, DPA1,DPB1, and allele specific antibodies to calculate CPRA.

Aim:

The aim of our study is to evaluae the effect of the new CPRA calculator on the rete of transplants in our sensitized and non-sensitized kidney patiiennnt population. We would like to determine the rate of transplantation in patients with different CPRA.

Methods:

The MFI of 5000 was used as the cutoff to list unacceptable antibodies. Approximately 1200 patients who were listed for transplant were evaluated. An average of 430 sensitized patients with CPRA>1% on the kidney and / or Pancreas waiting list were included in this study. The CPRA values prior to transplant was used for our evaluation.

Results:

The rate of patients with CPRA value of 99-100% were increased from 2022 to 2023 by 66%. The rate of transplant for sensitied recipients with CPRA values of 1-98% were increased by 6%. There was an increase in number of transplants in non-sensitized patients with CPRA of 0% with rare antibodies and no CPRA value.

Conclusions:

The new CPRA calculator appears to have a positive effect on the rate of transplant in highly sensitized recipients.

PERCENT OF TRANSPLANTED PATIENTS BASED ON CPRA				
	2022		2023	
CPRA	NO OF TXP	% TXP	No of TXP	% TXP
100+99		1.6		4.7
100	2	1.6	7	4.1
99	0	0	1	0.6
91-98	4	3.3	5	2.9
81-90	4	3.3	4	2.3
71-80	1	8	3	1.8
61-70	3	2.4	4	2.3
51-60	2	1.6	5	2.9
41-50	6	4.9	2	1.2
31-40	2	1.6	1	0.6
21-30	3	2.4	11	6.4
20-Nov	0	0	5	2.9
10-Jan	6	4.9	6	3.5
0	90	73.2	117	68.4

PERCENT OF PATIENTS TRANSPLANTED 2022-2023

100+99% CPRA